Regado Biosciences, which is developing break-through anticoagulant system for cardiovascular surgeries, raised $43 million by offering 10.8 million shares, 2.4 million more than anticipated, at $4, below its lowered $5 price. The company had initially filed to offer 5 million shares at a range of $14 to $16 before cutting the deal size 44% Monday morning. At its $4 offer price, Regado Biosciences commands a market cap of $82 million (63% below its initial proposed market cap) and will have approximately $52 million in cash.
